Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

S1693

Sigma-Aldrich

SU 9516

≥98% (HPLC), crystalline

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H11N3O2
CAS Number:
377090-84-1
Molecular Weight:
241.25
MDL number:
MFCD05865243
UNSPSC Code:
12352200
PubChem Substance ID:
24278633

assay

≥98% (HPLC)

form

crystalline

color

brown

solubility

DMSO: ~17 mg/mL
H2O: insoluble

SMILES string

COc1ccc2NC(=O)C(=C/c3cnc[nH]3)\c2c1

InChI

1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-7H,1H3,(H,14,15)(H,16,17)/b11-4-

InChI key

QNUKRWAIZMBVCU-WCIBSUBMSA-N

Gene Information

human ... CDK2(1017) , PDGFRB(5159) , SRC(6714)

Application

Identified through a high-throughput screening with Cdk2. IC50=22 nM.
SU 9516 may be used to study cyclin-dependent kinase-2-dependent cell signaling.

Biochem/physiol Actions

3-substituted indoline cyclin-dependent kinase-2 (Cdk2) inhibitor. Induces apoptosis in colon carcinoma cells.
The apoptosis induced by SU 9516 in colon carcinoma cells involves dephosphorylation of pRb and cell cycle arrest in G1 or G2/M phase. In human leukemia cells, SU 9516 induces release of cytochrome c, Bax translocation and causes mitochondrial injury.[1] It is being explored as an anti-cancer drug.[2]

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
113K4609

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yufu Zhu et al.
Journal of cellular and molecular medicine, 21(11), 2685-2694 (2017-05-05)
SH3GL2 (Src homology 3 (SH3) domain GRB2-like 2) is mainly expressed in the central nervous system and regarded as a tumour suppressor in human glioma. However, the molecular mechanism of the SH3GL2 protein involved in malignant behaviours of human glioma
Ning Gao et al.
Molecular pharmacology, 70(2), 645-655 (2006-05-05)
Mechanisms of lethality of the three-substituted indolinone and putatively selective cyclin-dependent kinase (CDK)2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) were examined in human leukemia cells. Exposure of U937 and other leukemia cells to SU9516 concentrations > or =5 microM rapidly (i.e., within 4
Tim Hunt
Cell cycle (Georgetown, Tex.), 7(24), 3789-3790 (2008-12-11)
Ever since it emerged that cyclin-dependent protein kinases catalyzed cell cycle transitions and with cancer seen as "a disease of the cell cycle," people have pursued the aim of testing kinase inhibitors as anti-cancer drugs. Quite early on, Laurent Meijer
Hengliang Shi et al.
Journal of cellular and molecular medicine, 18(10), 2061-2070 (2014-08-16)
Immunotherapy mediated by recombinant antibodies is an effective therapeutic strategy for a variety of cancers. In a previous study, we demonstrated that the fibroblast growth factor 1 (FGF-1)-specific recombinant antibody scFv1C9 arrests the cell cycle at the G0/G1 transition by

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service